FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $601,000 | -37.0% | 6,922 | -40.2% | 0.21% | +41.9% |
| Q1 2021 | $954,000 | +118.3% | 11,573 | +140.7% | 0.15% | +138.7% |
| Q4 2020 | $437,000 | -33.4% | 4,808 | -70.7% | 0.06% | -45.6% |
| Q3 2020 | $656,000 | +26.6% | 16,401 | +8.6% | 0.11% | +11.8% |
| Q2 2020 | $518,000 | +87.0% | 15,099 | +21.0% | 0.10% | -55.1% |
| Q1 2020 | $277,000 | -11.2% | 12,476 | -21.6% | 0.23% | +393.5% |
| Q4 2019 | $312,000 | +92.6% | 15,918 | +52.2% | 0.05% | +24.3% |
| Q3 2019 | $162,000 | -4.7% | 10,456 | -20.9% | 0.04% | -2.6% |
| Q4 2018 | $170,000 | +31.8% | 13,216 | +16.4% | 0.04% | +58.3% |
| Q2 2018 | $129,000 | – | 11,350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |